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parison to non-PEG. The incremental cost per QALY
gained is €4289. The weighted average incremental 
cost-effectiveness ratio, using population-based HCV
genotype distribution estimates, for all genotypes was
€9473 per QALY. CONCLUSION: Peginterferon alfa-2a
(40KD)/ribavirin is a cost-effective therapy for treatment
of naive adults with CHC compared with standard inter-
feron alfa-2b/ribavirin, regardless of HCV genotype.
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OBJECTIVES: Due to the high prevalence of hepatitis B
infection in some Asian countries and the associated 
morbidity and mortality, widespread treatment of chronic
hepatitis B treatment would have major public health
implications in these countries. We evaluated the cost-
effectiveness of 3 treatment regimens for chronic hepati-
tis B (interferon-alpha for 16 weeks, lamivudine for 
1 year, and lamivudine for 3 years) vs. no treatment 
in Taiwan, where government-sponsored universal 
health insurance have been implemented since 1995.
METHODS: We followed international guidelines on
cost-effectiveness analysis and constructed a Markov
model to project disease progression and health care
expenditure among hypothetical cohorts of 30-year-old
chronic hepatitis B patients. We adopted the societal 
perspective and a 70-year time frame since treatment 
initiation. Taiwan-speciﬁc disease, quality-of-life, and
costs information was used for virtually all model para-
meters. Outcome of interest was the Incremental Cost-
Effectiveness Ratio (ICER) in Taiwan Dollar (TWD,
US$1 = 34.41TWD on January 13, 2003) per QALY.
RESULTS: For a 30-year-old chronic hepatitis B patient
under base-case assumption, projected increase in life
expectancy was 1.84 years, 2.01 years, and 3.9 years if
s/he was treated with interferon, lamivudine for one year,
and lamivudine for three years, respectively. ICERs
(TWD/QALY) with 3% annual discount rate were 34,700
for interferon, 17,400 for 1 year of lamivudine, and
46,200 for 3 years of lamivudine. Monte Carlo simula-
tion showed robust results with respect to a wide range
of parameter assumptions and each of the three treatment
regimens could result in costs-savings. In multi-way sen-
sitivity analysis, the upper range of 95% of the ICERs
(with 3% annual discount rate) were 204,100 for inter-
feron, 127,800 for 1 year of lamivudine, and 197,900 for
3 years of lamivudine. CONCLUSIONS: Using lamivu-
dine to treat of chronic hepatitis B among young adults
in Taiwan would result in substantial gain in life
expectancy.
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OBJECTIVES: Approximately 350 million patients have
Chronic HBV infection worldwide. In Brazil there are
more than 3 million chronically infected with HBV. HBV
infection leads to chronic liver disease states such as cir-
rhosis, hepatocarcinoma and the need for transplanta-
tion. There is little published data on the cost of HBV in
Brazil. The aim of this study is to investigate treatments
patterns, medical resource use and treatment costs for
each state of HBV infection. METHODS: A question-
naire was developed and a physician survey conducted to
obtain information about the treatment patterns for
Chronic HBV in Brazil. Data were collected from physi-
cians in seven hospitals, across three different regions of
Brazil. Cost information was derived predominantly from
the government pay schedule; private hospital services
and pharmacy cost tables for medical care in Brazil.
RESULTS: Patients were separated into those managed
with and without antiviral medications. Lamivudine 
and Interferon alfa 2-B were the most common used
antiviral agents, with a cost of R$921.17 (year patient)
and R$15,424 (year/patient) respectively. The expected
annual costs per patient were: R$7,561 (R$1,030,
R$17,374) for chronic hepatitis B with antiviral medica-
tion, R$326 (R$212, R$512) for chronic hepatitis B
without antiviral medication, R$6,279 (R$1,030,
R$17,377) for compensated cirrhosis with antiviral 
medication, R$384 (R$212, R$555) for compensated 
cirrhosis without antiviral medication, R$16,522
(R$3,392, R$44,336) for decompensated cirrhosis,
R$39,895 (R$38,678, R$41,112) for liver transplanta-
tion, R$29,858 (R$26,513, R$33,202) for transplant
care after the ﬁrst year and R$2,382 (R$1,731, R$3,032)
for hepatocellular carcinoma. CONCLUSIONS: These
cost data can be used to model disease burden in Brazil.
Cost of antiviral medications inﬂuence disease costs in
chronic HBV and compensated cirrhosis states. Costs
increase dramatically in the more advanced health states,
and indicate that slowing progression to these states may
be cost savings. One USD = 3 R$ at the moment of the
survey.
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OBJECTIVES: Nearly 350 million people worldwide are
chronically infected with hepatitis B virus (HBV). In the
United States (US), the incidence of infection was esti-
mated at 240,000 new infections annually between 1988
and 1994. Complications of HBV infection, such as cir-
rhosis, liver failure and hepatocellular carcinoma, are the
cause of signiﬁcant morbidity and mortality and may
have important economic implications. As part of a multi-
national effort to examine the burden of HBV infection,
our objective was to estimate direct medical costs in the
US of six health states associated with HBV infection.
METHODS: We used administrative claims data (includ-
ing medical and pharmacy utilization) from a national
database (PharMetrics) to estimate costs for: 1) chronic
HBV; 2) compensated cirrhosis; 3) decompensated cir-
rhosis; 4) liver transplantation; 5) transplant care >12
months following transplant; and 6) hepatocellular carci-
noma. Patients with HBV were identiﬁed in each health
state using diagnostic and procedure codes speciﬁc to the
health state, and their utilization was tracked during their
time in that health state. To estimate costs, we used reim-
bursed (paid) amounts and adjusted to 2000 US dollars.
RESULTS: Average annual costs for patients in each
health state were: chronic HBV = $873; compensated cir-
rhosis = $305; decompensated cirrhosis = $15,102; liver
transplant = $126,278; transplant care >12 months fol-
lowing transplant = $15,660; and hepatocellular carci-
noma = $9478. Medications contributed the largest
proportion of costs in chronic HBV and compensated cir-
rhosis, while hospitalizations were the largest cost com-
ponent in the other health states. CONCLUSIONS: Our
analysis provides estimates of the annual costs of com-
plications of HBV infection in the US and suggests the
costs of certain HBV sequelae are signiﬁcant. The cost
estimates can be used in modeling studies, which estimate
the burden of illness of HBV and evaluate the cost-effec-
tiveness of interventions targeted at HBV.
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OBJECTIVE: Chronic HBV is a serious infection for
which few therapeutic options exist. The CDC estimates
that 1.25 million Americans are chronically infected. We
estimated the burden of disease in the United States from
chronic HBV and its complications such as cirrhosis and
hepatocellular carcinoma (HCC) using a disease simula-
tion model. METHODS: We analyzed US data from the
NHANES III survey to derive HBsAg prevalence esti-
mates for the age groups 20–29, 30–39, 40–49, 50–59,
60+. Using US census data from 1991, we estimated the
number of HBsAg carriers in the US in each age group.
A Markov model with eight health states (seroconversion;
chronic HBV; compensated cirrhosis; decompensated cir-
rhosis; HCC; transplant year 1; transplant year 2; death)
was used to estimate disease burden from 2002–2012.
Model simulation started from 1991; all subjects were
started from the chronic HBV state; cycle length was one
year; subjects could move between health states annually.
Transition probabilities were derived from literature.
Costs were derived from a claims database analysis (Phar-
metrics) and literature. RESULTS: We estimated that
653,101 people had chronic HBV infection in 1991.
These formed the base population for our analysis. We
estimated that from 2002–2012, there will be 133,661
cirrhosis cases; 41,101 HCC cases; 6653 liver transplants;
133,722 deaths attributable to chronic HBV infection.
The total direct medical costs for these cases was esti-
mated at $9.4B over the same time frame. CONCLU-
SIONS: The results of this analysis shows that HBV
infection is a signiﬁcant burden on the US healthcare
system. These results are probably an underestimation of
the true burden given that our estimated patient popula-
tion was half of the CDC estimate and incident cases are
not accounted for. The availability of an effective antivi-
ral agent capable of modifying the disease progression
would decrease this economic burden to society.
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OBJECTIVES: The objectives of this study are to examine
the clinical efﬁcacy of using an oral (PO) acyclovir pro-
phylactic herpes (HSV) protocol before a bone marrow
transplant (BMT) versus the intravenous (IV) formulation
of acyclovir, as well as the cost-savings that the oral for-
mulation has relative to the intravenous. METHODS:
Two retrospective cohorts were examined on the UCSF
Medical Center Adult BMT/Leukemia Service. The ﬁrst
cohort consisted of 31 patients on the service for either a
BMT or Peripheral Stem Cell Transplant (PSCT) in 1996.
These patients were started on an IV acyclovir prophy-
lactic protocol. The second cohort consisted of 41
patients on the same service for either a BMT or PSCT in
2001. These patients were started on an oral acyclovir
prophylactic protocol. The two main outcome variables
include cost per day of acyclovir treatment/prophylaxis
and percentage stay on IV acyclovir. Further analyses 
conducted include subgroup analysis, sensitivity analysis,
principal components analysis, linear regression, and an
exploratory analysis. RESULTS: This study found that
the oral protocol has similar clinical efﬁcacy (2 infection
in the PO group and 0 in the IV group) to the IV formu-
